Cancer News and Research

Latest Cancer News and Research

Mushrooms deliver nutrition medicine and sustainability solutions in one package

This Food Science & Nutrition review highlights mushrooms as nutrient-rich functional foods packed with bioactive compounds that support human health. It explores their therapeutic, industrial, and environmental applications, from disease prevention and drug discovery to bioremediation and bioenergy.

8 Sep 2025

New strategy for difficult-to-treat mesothelioma: Immunotherapy and ctDNA insights

People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the role of surgery for this difficult to treat cancer.

8 Sep 2025

Many patients undergoing surgery for early-stage cancer continue or start opioid prescriptions

New research indicates that many patients who undergo surgery with the intent to cure early-stage cancer continue or start opioid prescriptions in the year following surgery.

8 Sep 2025

New technology could make MRI scanners cost-effective and more accessible

Revolutionary new technology could make MRI scanners cost effective, more widely available to local communities and help save lives, thanks to a pioneering collaboration between the University of Sheffield and GE HealthCare.

8 Sep 2025

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

8 Sep 2025

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC).

8 Sep 2025

Study could pave the way for simple blood test to diagnose Alzheimer's disease

In a landmark study of Hispanic and Latino adults, researchers at University of California San Diego School of Medicine have identified a link between self-reported cognitive decline and blood-based biomarkers, which could pave the way for a simple blood test to help diagnose Alzheimer's disease and related dementias.

8 Sep 2025

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.

8 Sep 2025

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

8 Sep 2025

Nicotine pouch use may be a step toward reducing more dangerous forms of tobacco

As lawmakers and public health experts debate the safety of nicotine pouches, researchers from Rutgers Health found that for now, most adults that use these products also have a history of tobacco use and may be choosing these products as a possible step toward reducing or quitting more dangerous forms of nicotine delivery.

8 Sep 2025

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

8 Sep 2025

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

8 Sep 2025

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).

8 Sep 2025

Study validates deep learning model for predicting future lung cancer risk in Black population

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) validates the use of Sybil, a deep learning artificial intelligence model, for predicting future lung cancer risk in a predominantly Black population.

8 Sep 2025

Older patients eligible for surgery can benefit from lung cancer screening programs

Older individuals between the ages of 75 and 80 who are eligible for lung surgery may achieve survival outcomes comparable to younger patients following lung cancer screening, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

8 Sep 2025

Video-assisted thoracoscopic surgery provides improved overall survival compared to open lobectomy

Patients who underwent video-assisted thoracoscopic surgery (VATS) compared to open lobectomy had a significantly improved overall survival rate, according to a meta-analysis presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

8 Sep 2025

Frailty and microbial imbalance drive GI complications in bladder cancer surgery

Gastrointestinal (GI) complications, such as postoperative ileus (POI) and intra-abdominal infections (IAI), remain a major concern after radical cystectomy for bladder cancer.

8 Sep 2025

BioDlink fast-tracks global growth with bevacizumab launch in Colombia and Pakistan

BioDlink announced that its self-developed bevacizumab injection biosimilar has received marketing approval from Colombia’s National Institute for Surveillance of Medicines and Foods (INVIMA) and Pakistan’s Drug Regulatory Authority of Pakistan (DRAP).

From BioDlink 8 Sep 2025

New drug candidate STF 1623 activates innate immunity in solid tumors

Cancer immunotherapy, which primes the body's immune system to fight off tumors, has historically focused on harnessing T cells' natural ability to recognize and attack cancer cells.

5 Sep 2025

NYU Langone strengthens world-leading GI cancer program with renowned leaders

NYU Langone Health's Perlmutter Cancer Center announces the arrival of acclaimed cancer leaders Anirban Maitra, MD, and Manuel Hidalgo, MD, as co-directors of a new Gastrointestinal (GI) Cancer Center.

5 Sep 2025

Previous
1
...
52
53
54
55
56
57
58
...
4607
Next

Cancer News and Research

Latest Cancer News and Research

Mushrooms deliver nutrition medicine and sustainability solutions in one package

New strategy for difficult-to-treat mesothelioma: Immunotherapy and ctDNA insights

Many patients undergoing surgery for early-stage cancer continue or start opioid prescriptions

New technology could make MRI scanners cost-effective and more accessible

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

Study could pave the way for simple blood test to diagnose Alzheimer's disease

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Nicotine pouch use may be a step toward reducing more dangerous forms of tobacco

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Study validates deep learning model for predicting future lung cancer risk in Black population

Older patients eligible for surgery can benefit from lung cancer screening programs

Video-assisted thoracoscopic surgery provides improved overall survival compared to open lobectomy

Frailty and microbial imbalance drive GI complications in bladder cancer surgery

BioDlink fast-tracks global growth with bevacizumab launch in Colombia and Pakistan

New drug candidate STF 1623 activates innate immunity in solid tumors

NYU Langone strengthens world-leading GI cancer program with renowned leaders

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in